APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anti-Obesity Drugs (Anti-obesity Medication)

Compare research editions
View pricing & licenses

Selected research

Industry Research

Anti-Obesity Drugs (Anti-obesity Medication) Industry Research Report 2026

20 December 2025150 pages

Choose your research edition.

Industry ResearchAnti-Obesity Drugs (Anti-obesity Medication) Industry Research Report 2026150 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-Obesity Drugs (Anti-obesity Medication) Industry Growth and Trends Forecast to 2032126 pages · $3,450 USDMarket StructureGlobal Anti-Obesity Drugs (Anti-obesity Medication) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-Obesity Drugs (Anti-obesity Medication) Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-Obesity Drugs (Anti-obesity Medication) Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

The global Anti-Obesity Drugs (Anti-obesity Medication) market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Anti-Obesity Drugs (Anti-obesity Medication) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Anti-Obesity Drugs (Anti-obesity Medication) is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Anti-Obesity Drugs (Anti-obesity Medication) is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Anti-Obesity Drugs (Anti-obesity Medication) include Eisai, Sanofi, Novo Nordisk, Merck, F.Hoffmann-La Roche, Pfizer, GlaxoSmithKline, Bayer AG and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Anti-Obesity Drugs (Anti-obesity Medication) market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Anti-Obesity Drugs (Anti-obesity Medication) Market by Company

Eisai

Sanofi

Novo Nordisk

Merck

F.Hoffmann-La Roche

Pfizer

GlaxoSmithKline

Bayer AG

AstraZeneca

Zafgan

Vivus

Shionogi

Rhythm Pharmaceuticals

Orexigen Therapeutics

Norgine

Boehringer Ingelheim

Arena Pharmaceuticals

Amylin

Alizyme

Alizyme

Anti-Obesity Drugs (Anti-obesity Medication) Segment by Type

Rx Drug

OTC Drug

Anti-Obesity Drugs (Anti-obesity Medication) Segment by Application

Middle Aged (41-60)

Juvenile (7-17)

Youth (18-40)

Elderly (Above 60)

Childhood (0-6)

Anti-Obesity Drugs (Anti-obesity Medication) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-Obesity Drugs (Anti-obesity Medication) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-Obesity Drugs (Anti-obesity Medication) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-Obesity Drugs (Anti-obesity Medication).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Anti-Obesity Drugs (Anti-obesity Medication) manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Anti-Obesity Drugs (Anti-obesity Medication) by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Anti-Obesity Drugs (Anti-obesity Medication) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Anti-Obesity Drugs (Anti-obesity Medication) Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units) of Manufacturers (2021-2026) Table 7. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Manufacturers (2021-2026) Table 8. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue of Manufacturers (2021-2026) Table 9. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Anti-Obesity Drugs (Anti-obesity Medication) Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global Anti-Obesity Drugs (Anti-obesity Medication) Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Anti-Obesity Drugs (Anti-obesity Medication), Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Anti-Obesity Drugs (Anti-obesity Medication), Product Type & Application Table 14. Global Anti-Obesity Drugs (Anti-obesity Medication) Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Anti-Obesity Drugs (Anti-obesity Medication) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Eisai Company Information Table 19. Eisai Business Overview Table 20. Eisai Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. Eisai Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 22. Eisai Recent Developments Table 23. Sanofi Company Information Table 24. Sanofi Business Overview Table 25. Sanofi Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. Sanofi Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 27. Sanofi Recent Developments Table 28. Novo Nordisk Company Information Table 29. Novo Nordisk Business Overview Table 30. Novo Nordisk Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 31. Novo Nordisk Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 32. Novo Nordisk Recent Developments Table 33. Merck Company Information Table 34. Merck Business Overview Table 35. Merck Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 36. Merck Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 37. Merck Recent Developments Table 38. F.Hoffmann-La Roche Company Information Table 39. F.Hoffmann-La Roche Business Overview Table 40. F.Hoffmann-La Roche Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 41. F.Hoffmann-La Roche Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 42. F.Hoffmann-La Roche Recent Developments Table 43. Pfizer Company Information Table 44. Pfizer Business Overview Table 45. Pfizer Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. Pfizer Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 47. Pfizer Recent Developments Table 48. GlaxoSmithKline Company Information Table 49. GlaxoSmithKline Business Overview Table 50. GlaxoSmithKline Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 51. GlaxoSmithKline Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 52. GlaxoSmithKline Recent Developments Table 53. Bayer AG Company Information Table 54. Bayer AG Business Overview Table 55. Bayer AG Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 56. Bayer AG Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 57. Bayer AG Recent Developments Table 58. AstraZeneca Company Information Table 59. AstraZeneca Business Overview Table 60. AstraZeneca Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 61. AstraZeneca Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 62. AstraZeneca Recent Developments Table 63. Zafgan Company Information Table 64. Zafgan Business Overview Table 65. Zafgan Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Zafgan Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 67. Zafgan Recent Developments Table 68. Vivus Company Information Table 69. Vivus Business Overview Table 70. Vivus Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Vivus Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 72. Vivus Recent Developments Table 73. Shionogi Company Information Table 74. Shionogi Business Overview Table 75. Shionogi Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Shionogi Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 77. Shionogi Recent Developments Table 78. Rhythm Pharmaceuticals Company Information Table 79. Rhythm Pharmaceuticals Business Overview Table 80. Rhythm Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Rhythm Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 82. Rhythm Pharmaceuticals Recent Developments Table 83. Orexigen Therapeutics Company Information Table 84. Orexigen Therapeutics Business Overview Table 85. Orexigen Therapeutics Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Orexigen Therapeutics Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 87. Orexigen Therapeutics Recent Developments Table 88. Norgine Company Information Table 89. Norgine Business Overview Table 90. Norgine Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Norgine Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 92. Norgine Recent Developments Table 93. Boehringer Ingelheim Company Information Table 94. Boehringer Ingelheim Business Overview Table 95. Boehringer Ingelheim Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Boehringer Ingelheim Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 97. Boehringer Ingelheim Recent Developments Table 98. Arena Pharmaceuticals Company Information Table 99. Arena Pharmaceuticals Business Overview Table 100. Arena Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Arena Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 102. Arena Pharmaceuticals Recent Developments Table 103. Amylin Company Information Table 104. Amylin Business Overview Table 105. Amylin Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. Amylin Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 107. Amylin Recent Developments Table 108. Alizyme Company Information Table 109. Alizyme Business Overview Table 110. Alizyme Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 111. Alizyme Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 112. Alizyme Recent Developments Table 113. Alizyme Company Information Table 114. Alizyme Business Overview Table 115. Alizyme Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 116. Alizyme Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 117. Alizyme Recent Developments Table 118. Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 119. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Region (2021-2026) & (k units) Table 120. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Region (2021-2026) Table 121. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Region (2027-2032) & (k units) Table 122. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Region (2027-2032) Table 123. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Region (2021-2026) & (US$ Million) Table 124. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Region (2021-2026) Table 125. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Region (2027-2032) & (US$ Million) Table 126. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Region (2027-2032) Table 127. North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2021-2026) & (k units) Table 129. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2027-2032) & (k units) Table 130. North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country (2021-2026) & (US$ Million) Table 131. North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country (2027-2032) & (US$ Million) Table 132. Europe Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2021-2026) & (k units) Table 134. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2027-2032) & (k units) Table 135. Europe Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country (2021-2026) & (US$ Million) Table 136. Europe Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country (2027-2032) & (US$ Million) Table 137. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2021-2026) & (k units) Table 139. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2027-2032) & (k units) Table 140. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country (2021-2026) & (US$ Million) Table 141. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country (2027-2032) & (US$ Million) Table 142. South America Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 143. South America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2021-2026) & (k units) Table 144. South America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2027-2032) & (k units) Table 145. South America Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country (2021-2026) & (US$ Million) Table 146. South America Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country (2027-2032) & (US$ Million) Table 147. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 148. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2021-2026) & (k units) Table 149. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2027-2032) & (k units) Table 150. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country (2021-2026) & (US$ Million) Table 151. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country (2027-2032) & (US$ Million) Table 152. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2021-2026) & (k units) Table 153. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2027-2032) & (k units) Table 154. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Type (2021-2026) Table 155. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Type (2027-2032) Table 156. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2021-2026) & (US$ Million) Table 157. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2027-2032) & (US$ Million) Table 158. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Type (2021-2026) Table 159. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Type (2027-2032) Table 160. Global Anti-Obesity Drugs (Anti-obesity Medication) Price by Type (2021-2026) & (US$/unit) Table 161. Global Anti-Obesity Drugs (Anti-obesity Medication) Price by Type (2027-2032) & (US$/unit) Table 162. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2021-2026) & (k units) Table 163. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2027-2032) & (k units) Table 164. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Application (2021-2026) Table 165. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Application (2027-2032) Table 166. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application (2021-2026) & (US$ Million) Table 167. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application (2027-2032) & (US$ Million) Table 168. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Application (2021-2026) Table 169. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Application (2027-2032) Table 170. Global Anti-Obesity Drugs (Anti-obesity Medication) Price by Application (2021-2026) & (US$/unit) Table 171. Global Anti-Obesity Drugs (Anti-obesity Medication) Price by Application (2027-2032) & (US$/unit) Table 172. Key Raw Materials Table 173. Raw Materials Key Suppliers Table 174. Anti-Obesity Drugs (Anti-obesity Medication) Distributors List Table 175. Anti-Obesity Drugs (Anti-obesity Medication) Customers List Table 176. Anti-Obesity Drugs (Anti-obesity Medication) Industry Trends Table 177. Anti-Obesity Drugs (Anti-obesity Medication) Industry Drivers Table 178. Anti-Obesity Drugs (Anti-obesity Medication) Industry Restraints Table 179. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Anti-Obesity Drugs (Anti-obesity Medication) Product Image Figure 5. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size (2021-2032) & (US$ Million) Figure 7. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales (2021-2032) & (k units) Figure 8. Global Anti-Obesity Drugs (Anti-obesity Medication) Average Price (US$/unit) & (2021-2032) Figure 9. Rx Drug Product Image Figure 10. OTC Drug Product Image Figure 11. Middle Aged (41-60) Product Image Figure 12. Juvenile (7-17) Product Image Figure 13. Youth (18-40) Product Image Figure 14. Elderly (Above 60) Product Image Figure 15. Childhood (0-6) Product Image Figure 16. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Share by Manufacturers in 2025 Figure 17. Global Manufacturers of Anti-Obesity Drugs (Anti-obesity Medication), Manufacturing Sites & Headquarters Figure 18. Global Top 5 and 10 Anti-Obesity Drugs (Anti-obesity Medication) Players Market Share by Revenue in 2025 Figure 19. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 21. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Region in 2025 Figure 22. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Region in 2025 Figure 23. North America Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Country in 2025 Figure 24. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Country (2021-2032) Figure 25. North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Country (2021-2032) Figure 26. United States Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Canada Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Mexico Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Europe Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Country in 2025 Figure 30. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Country (2021-2032) Figure 31. Europe Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Country (2021-2032) Figure 32. Germany Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. France Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. U.K. Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Italy Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Russia Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Spain Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Netherlands Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Switzerland Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Sweden Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Poland Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Country in 2025 Figure 43. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Country (2021-2032) Figure 44. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Country (2021-2032) Figure 45. China Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Japan Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. South Korea Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. India Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Australia Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Taiwan Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Southeast Asia Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. South America Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Country in 2025 Figure 54. South America Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Country (2021-2032) Figure 55. South America Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Country (2021-2032) Figure 56. Brazil Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Argentina Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Chile Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Country in 2025 Figure 60. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Country (2021-2032) Figure 61. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Country (2021-2032) Figure 62. Egypt Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. South Africa Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Israel Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Türkiye Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. GCC Countries Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Type (2021-2032) Figure 68. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Type (2021-2032) Figure 69. Global Anti-Obesity Drugs (Anti-obesity Medication) Price (US$/unit) by Type (2021-2032) Figure 70. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Application (2021-2032) Figure 71. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Application (2021-2032) Figure 72. Global Anti-Obesity Drugs (Anti-obesity Medication) Price (US$/unit) by Application (2021-2032) Figure 73. Anti-Obesity Drugs (Anti-obesity Medication) Value Chain Figure 74. Anti-Obesity Drugs (Anti-obesity Medication) Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Anti-Obesity Drugs (Anti-obesity Medication) Industry Opportunities and Challenges

Scope & coverage.

Types
  • Rx Drug
  • OTC Drug
Applications
  • Middle Aged (41-60)
  • Juvenile (7-17)
  • Youth (18-40)
  • Elderly (Above 60)
  • Childhood (0-6)
Companies covered
  • Eisai
  • Sanofi
  • Novo Nordisk
  • Merck
  • F.Hoffmann-La Roche
  • Pfizer
  • GlaxoSmithKline
  • Bayer AG
  • AstraZeneca
  • Zafgan
  • Vivus
  • Shionogi
  • Rhythm Pharmaceuticals
  • Orexigen Therapeutics
  • Norgine
  • Boehringer Ingelheim
  • Arena Pharmaceuticals
  • Amylin
  • Alizyme
  • Alizyme

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size (2021-2032)
  4. 2.2.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales (2021-2032)
  5. 2.2.3 Global Anti-Obesity Drugs (Anti-obesity Medication) Market Average Price (2021-2032)
  6. 2.3 Anti-Obesity Drugs (Anti-obesity Medication) by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Rx Drug
  9. 2.3.3 OTC Drug
  10. 2.4 Anti-Obesity Drugs (Anti-obesity Medication) by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Middle Aged (41-60)
  13. 2.4.3 Juvenile (7-17)
  14. 2.4.4 Youth (18-40)
  15. 2.4.5 Elderly (Above 60)
  16. 2.4.6 Childhood (0-6)
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Anti-Obesity Drugs (Anti-obesity Medication) Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Anti-Obesity Drugs (Anti-obesity Medication) Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Anti-Obesity Drugs (Anti-obesity Medication), Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Anti-Obesity Drugs (Anti-obesity Medication), Product Type & Application
  8. 3.8 Global Manufacturers of Anti-Obesity Drugs (Anti-obesity Medication), Established Date
  9. 3.9 Global Anti-Obesity Drugs (Anti-obesity Medication) Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Eisai
  2. 4.1.1 Eisai Company Information
  3. 4.1.2 Eisai Business Overview
  4. 4.1.3 Eisai Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Eisai Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  6. 4.1.5 Eisai Recent Developments
  7. 4.2 Sanofi
  8. 4.2.1 Sanofi Company Information
  9. 4.2.2 Sanofi Business Overview
  10. 4.2.3 Sanofi Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Sanofi Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  12. 4.2.5 Sanofi Recent Developments
  13. 4.3 Novo Nordisk
  14. 4.3.1 Novo Nordisk Company Information
  15. 4.3.2 Novo Nordisk Business Overview
  16. 4.3.3 Novo Nordisk Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Novo Nordisk Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  18. 4.3.5 Novo Nordisk Recent Developments
  19. 4.4 Merck
  20. 4.4.1 Merck Company Information
  21. 4.4.2 Merck Business Overview
  22. 4.4.3 Merck Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Merck Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  24. 4.4.5 Merck Recent Developments
  25. 4.5 F.Hoffmann-La Roche
  26. 4.5.1 F.Hoffmann-La Roche Company Information
  27. 4.5.2 F.Hoffmann-La Roche Business Overview
  28. 4.5.3 F.Hoffmann-La Roche Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 F.Hoffmann-La Roche Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  30. 4.5.5 F.Hoffmann-La Roche Recent Developments
  31. 4.6 Pfizer
  32. 4.6.1 Pfizer Company Information
  33. 4.6.2 Pfizer Business Overview
  34. 4.6.3 Pfizer Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Pfizer Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  36. 4.6.5 Pfizer Recent Developments
  37. 4.7 GlaxoSmithKline
  38. 4.7.1 GlaxoSmithKline Company Information
  39. 4.7.2 GlaxoSmithKline Business Overview
  40. 4.7.3 GlaxoSmithKline Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 GlaxoSmithKline Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  42. 4.7.5 GlaxoSmithKline Recent Developments
  43. 4.8 Bayer AG
  44. 4.8.1 Bayer AG Company Information
  45. 4.8.2 Bayer AG Business Overview
  46. 4.8.3 Bayer AG Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Bayer AG Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  48. 4.8.5 Bayer AG Recent Developments
  49. 4.9 AstraZeneca
  50. 4.9.1 AstraZeneca Company Information
  51. 4.9.2 AstraZeneca Business Overview
  52. 4.9.3 AstraZeneca Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 AstraZeneca Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  54. 4.9.5 AstraZeneca Recent Developments
  55. 4.10 Zafgan
  56. 4.10.1 Zafgan Company Information
  57. 4.10.2 Zafgan Business Overview
  58. 4.10.3 Zafgan Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Zafgan Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  60. 4.10.5 Zafgan Recent Developments
  61. 4.11 Vivus
  62. 4.11.1 Vivus Company Information
  63. 4.11.2 Vivus Business Overview
  64. 4.11.3 Vivus Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Vivus Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  66. 4.11.5 Vivus Recent Developments
  67. 4.12 Shionogi
  68. 4.12.1 Shionogi Company Information
  69. 4.12.2 Shionogi Business Overview
  70. 4.12.3 Shionogi Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Shionogi Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  72. 4.12.5 Shionogi Recent Developments
  73. 4.13 Rhythm Pharmaceuticals
  74. 4.13.1 Rhythm Pharmaceuticals Company Information
  75. 4.13.2 Rhythm Pharmaceuticals Business Overview
  76. 4.13.3 Rhythm Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Rhythm Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  78. 4.13.5 Rhythm Pharmaceuticals Recent Developments
  79. 4.14 Orexigen Therapeutics
  80. 4.14.1 Orexigen Therapeutics Company Information
  81. 4.14.2 Orexigen Therapeutics Business Overview
  82. 4.14.3 Orexigen Therapeutics Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Orexigen Therapeutics Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  84. 4.14.5 Orexigen Therapeutics Recent Developments
  85. 4.15 Norgine
  86. 4.15.1 Norgine Company Information
  87. 4.15.2 Norgine Business Overview
  88. 4.15.3 Norgine Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Norgine Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  90. 4.15.5 Norgine Recent Developments
  91. 4.16 Boehringer Ingelheim
  92. 4.16.1 Boehringer Ingelheim Company Information
  93. 4.16.2 Boehringer Ingelheim Business Overview
  94. 4.16.3 Boehringer Ingelheim Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Boehringer Ingelheim Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  96. 4.16.5 Boehringer Ingelheim Recent Developments
  97. 4.17 Arena Pharmaceuticals
  98. 4.17.1 Arena Pharmaceuticals Company Information
  99. 4.17.2 Arena Pharmaceuticals Business Overview
  100. 4.17.3 Arena Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Arena Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  102. 4.17.5 Arena Pharmaceuticals Recent Developments
  103. 4.18 Amylin
  104. 4.18.1 Amylin Company Information
  105. 4.18.2 Amylin Business Overview
  106. 4.18.3 Amylin Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Amylin Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  108. 4.18.5 Amylin Recent Developments
  109. 4.19 Alizyme
  110. 4.19.1 Alizyme Company Information
  111. 4.19.2 Alizyme Business Overview
  112. 4.19.3 Alizyme Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 Alizyme Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  114. 4.19.5 Alizyme Recent Developments
  115. 4.20 Alizyme
  116. 4.20.1 Alizyme Company Information
  117. 4.20.2 Alizyme Business Overview
  118. 4.20.3 Alizyme Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2021-2026)
  119. 4.20.4 Alizyme Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  120. 4.20.5 Alizyme Recent Developments
5 Global Anti-Obesity Drugs (Anti-obesity Medication) Market Scenario by Region
  1. 5.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Region: 2021-2032
  3. 5.2.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Region: 2021-2026
  4. 5.2.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Region: 2027-2032
  5. 5.3 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Region: 2021-2032
  6. 5.3.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Region: 2021-2026
  7. 5.3.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Region: 2027-2032
  8. 5.4 North America Anti-Obesity Drugs (Anti-obesity Medication) Market Facts & Figures by Country
  9. 5.4.1 North America Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2021-2032)
  11. 5.4.3 North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Anti-Obesity Drugs (Anti-obesity Medication) Market Facts & Figures by Country
  16. 5.5.1 Europe Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2021-2032)
  18. 5.5.3 Europe Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Anti-Obesity Drugs (Anti-obesity Medication) Market Facts & Figures by Country
  41. 5.7.1 South America Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2021-2032)
  43. 5.7.3 South America Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2021-2032)
  2. 6.1.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Type (2021-2032)
  4. 6.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2021-2032)
  5. 6.2.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Anti-Obesity Drugs (Anti-obesity Medication) Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2021-2032)
  2. 7.1.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Application (2021-2032)
  4. 7.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application (2021-2032)
  5. 7.2.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Anti-Obesity Drugs (Anti-obesity Medication) Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Anti-Obesity Drugs (Anti-obesity Medication) Value Chain Analysis
  2. 8.1.1 Anti-Obesity Drugs (Anti-obesity Medication) Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Anti-Obesity Drugs (Anti-obesity Medication) Production Mode & Process
  5. 8.2 Anti-Obesity Drugs (Anti-obesity Medication) Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Anti-Obesity Drugs (Anti-obesity Medication) Distributors
  8. 8.2.3 Anti-Obesity Drugs (Anti-obesity Medication) Customers
9 Global Anti-Obesity Drugs (Anti-obesity Medication) Analyzing Market Dynamics
  1. 9.1 Anti-Obesity Drugs (Anti-obesity Medication) Industry Trends
  2. 9.2 Anti-Obesity Drugs (Anti-obesity Medication) Industry Drivers
  3. 9.3 Anti-Obesity Drugs (Anti-obesity Medication) Industry Opportunities and Challenges
  4. 9.4 Anti-Obesity Drugs (Anti-obesity Medication) Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst